Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients

Journal of Translational Medicine

Volumn 9, Issue , 2011, Pages

  Sigalotti, Luca ^a   Fratta, Elisabetta ^a   Bidoli, Ettore ^a   Covre, Alessia ^a,c   Parisi, Giulia ^a,c   Colizzi, Francesca ^a   Coral, Sandra ^a   Massarut, Samuele ^a   Kirkwood, John M ^b   Maio, Michele ^a,c  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LACTATE DEHYDROGENASE; MESSENGER RNA;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; FEMALE; HUMAN; HUMAN CELL; LONG INTERSPERSED NUCLEOTIDE ELEMENT 1 SEQUENCE; LONG INTERSPERSED REPEAT; MALE; MELANOMA; MICROMETASTASIS; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; PYROSEQUENCING; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; TUMOR LOCALIZATION; DNA SEQUENCE; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SKIN TUMOR;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LONG INTERSPERSED NUCLEOTIDE ELEMENTS; MALE; MELANOMA; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RNA, MESSENGER; SEQUENCE ANALYSIS, DNA; SKIN NEOPLASMS;

EID: 79957511058     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-78     Document Type: Article

References (35)

1. MacKie RM, Hauschild A, Eggermont AMM. Epidemiology of invasive cutaneous melanoma. Ann Oncol 2009, 20:vi1-vi7. 10.1093/annonc/mdp252, 2712590, 19617292.
2. Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview. Oncology (WillistonPark) 2009, 23:488-496.
3. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Kirkwood JM, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. JClin Oncol 2001, 19:3635-3648.
4. Jennings L, Murphy GM. Predicting outcome in melanoma: where are we now?. BrJ Dermatol 2009,
5. Esteller M. Epigenetics in cancer. NEnglJ Med 2008, 358:1148-1159.
6. Gama-Sosa MA, Slagel VA, Trewyn RW, Oxenhandler R, Kuo KC, Gehrke CW, Ehrlich M. The 5-methylcytosine content of DNA from human tumors. NuclAcids Res 1983, 11:6883-6894.
7. Yang AS, Estecio MR, Doshi K, Kondo Y, Tajara EH, Issa JP. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res 2004, 32:e38. 10.1093/nar/gnh032, 373427, 14973332.
8. Cho NY, Kim JH, Moon KC, Kang GH. Genomic hypomethylation and CpG island hypermethylation in prostatic intraepithelial neoplasm. Virchows Arch 2009, 454:17-23. 10.1007/s00428-008-0706-6, 19048291.
9. Park SY, Yoo EJ, Cho NY, Kim N, Kang GH. Comparison of CpG island hypermethylation and repetitive DNA hypomethylation in premalignant stages of gastric cancer, stratified for Helicobacter pylori infection. JPathol 2009, 219:410-416.
10. Pattamadilok J, Huapai N, Rattanatanyong P, Vasurattana A, Triratanachat S, Tresukosol D, Mutirangura A. LINE-1 hypomethylation level as a potential prognostic factor for epithelial ovarian cancer. IntJ GynecolCancer 2008, 18:711-717.
11. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Chan AT, Schernhammer ES, Giovannucci EL, Fuchs CS. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. JNatlCancer Inst 2008, 100:1734-1738.
12. Altomonte M, Gloghini A, Bertola G, Gasparollo A, Carbone A, Ferrone S, Maio M. Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells. Cancer Res 1993, 53:3343-3348.
13. Ausubel FM, Brent R, Kingston RE, et al. Current Protocols in Molecular Biology 1998, New York: John Wiley & Sons.
14. Aparicio A, North B, Barske L, Wang X, Bollati V, Weisenberger D, Yoo C, Tannir N, Horne E, Groshen S, et al. LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors. Epigenetics 2009, 4:176-184. 10.4161/epi.4.3.8694, 2848123, 19421002.
15. Fratta E, Sigalotti L, Colizzi F, Covre A, Nicolay HJ, Danielli R, Fonsatti E, Altomonte M, Calabro L, Coral S, Maio M. Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma. J Cell Physiol 2010, 223:352-358.
16. Aporntewan C, Phokaew C, Piriyapongsa J, Ngamphiw C, Ittiwut C, Tongsima S, Mutirangura A. Hypomethylation of intragenic LINE-1 represses transcription in cancer cells through AGO2. PLoS One 2011, 6:e17934. 10.1371/journal.pone.0017934, 3057998, 21423624.
17. Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations. Journal of the American Statistical Association 1958, 53:457-481.
18. Cox DR. Regression models and life-tables (with discusssion). J Roy Statist Soc B 1972, 34:187-220.
19. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo JA, Navarro G, Garate L, Jose-Eneriz ES, Cordeu L, Barrios M, Prosper F, et al. Promoter hypermethylation and global hypomethylation are independent epigenetic events in lymphoid leukemogenesis with opposing effects on clinical outcome. Leukemia 2006, 20:1445-1448. 10.1038/sj.leu.2404257, 16688225.
20. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Cervantes F, Sanchez J, Garate L, Barrios M, Castillejo JA, Navarro G, Colomer D, et al. Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. Oncogene 2005, 24:7213-7223. 10.1038/sj.onc.1208866, 16170379.
21. Tellez CS, Shen L, Estecio MR, Jelinek J, Gershenwald JE, Issa JP. CpG island methylation profiling in human melanoma cell lines. Melanoma Res 2009, 19:146-155. 10.1097/CMR.0b013e32832b274e, 19441164.
22. Mori T, O'Day SJ, Umetani N, Martinez SR, Kitago M, Koyanagi K, Kuo C, Takeshima TL, Milford R, Wang HJ, et al. Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. J Clin Oncol 2005, 23:9351-9358. 10.1200/JCO.2005.02.9876, 2856438, 16361635.
23. Mori T, Martinez SR, O'Day SJ, Morton DL, Umetani N, Kitago M, Tanemura A, Nguyen SL, Tran AN, Wang HJ, Hoon DS. Estrogen receptor-alpha methylation predicts melanoma progression. Cancer Res 2006, 66:6692-6698. 10.1158/0008-5472.CAN-06-0801, 2856460, 16818643.
24. Tanemura A, Terando AM, Sim MS, van Hoesel AQ, de Maat MF, Morton DL, Hoon DS. CpG island methylator phenotype predicts progression of malignant melanoma. Clin Cancer Res 2009, 15:1801-1807. 10.1158/1078-0432.CCR-08-1361, 2703821, 19223509.
25. Wallace NA, Belancio VP, Deininger PL. L1 mobile element expression causes multiple types of toxicity. Gene 2008, 419:75-81. 10.1016/j.gene.2008.04.013, 18555620.
26. De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F, Boon T. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc NatlAcadSciUSA 1996, 93:7149-7153.
27. Sigalotti L, Coral S, Nardi G, Spessotto A, Cortini E, Cattarossi I, Colizzi F, Altomonte M, Maio M. Promoter methylation controls the expression of MAGE2, 3 and 4 genes in human cutaneous melanoma. JImmunother(1997) 2002, 25:16-26.
28. Woloszynska-Read A, Mhawech-Fauceglia P, Yu J, Odunsi K, Karpf AR. Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer. ClinCancer Res 2008, 14:3283-3290.
29. Sigalotti L, Covre A, Zabierowski S, Himes B, Colizzi F, Natali PG, Herlyn M, Maio M. Cancer testis antigens in human melanoma stem cells: expression, distribution, and methylation status. J Cell Physiol 2008, 215:287-291. 10.1002/jcp.21380, 18205182.
30. Sigalotti L, Covre A, Fratta E, Parisi G, Colizzi F, Rizzo A, Danielli R, Nicolay HJ, Coral S, Maio M. Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies. J Transl Med 2010, 8:56. 10.1186/1479-5876-8-56, 2901206, 20540720.
31. Fonsatti E, Nicolay HJ, Sigalotti L, Calabro L, Pezzani L, Colizzi F, Altomonte M, Guidoboni M, Marincola FM, Maio M. Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Clin Cancer Res 2007, 13:3333-3338. 10.1158/1078-0432.CCR-06-3091, 17545540.
32. John T, Black MA, Toro TT, Leader D, Gedye CA, Davis ID, Guilford PJ, Cebon JS. Predicting clinical outcome through molecular profiling in stage III melanoma. Clinical cancer research: an official journal of the American Association for Cancer Research 2008, 14:5173-5180.
33. Jonsson G, Busch C, Knappskog S, Geisler J, Miletic H, Ringner M, Lillehaug JR, Borg A, Lonning PE. Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clinical cancer research: an official journal of the American Association for Cancer Research 2010, 16:3356-3367.
34. Mandruzzato S, Callegaro A, Turcatel G, Francescato S, Montesco MC, Chiarion-Sileni V, Mocellin S, Rossi CR, Bicciato S, Wang E, et al. A gene expression signature associated with survival in metastatic melanoma. Journal of translational medicine 2006, 4:50. 10.1186/1479-5876-4-50, 1697826, 17129373.
35. Sigalotti L, Fratta E, Coral S, Cortini E, Covre A, Nicolay HJ, Anzalone L, Pezzani L, Di Giacomo AM, Fonsatti E, et al. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. J Cell Physiol 2007, 212:330-344. 10.1002/jcp.21066, 17458893.